Alembic Pharmaceuticals' Q3 FY 2025-26 Quarterly Results

Result Summary

• Alembic Pharmaceuticals Ltd reported a 1.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.1%.
• Its expenses for the quarter were down by 0.5% QoQ and up 10.6% YoY.
• The net profit decreased 28.2% QoQ and decreased 4.2% YoY.
• The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 6.76 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alembic Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry. The company is primarily engaged in the manufacturing and marketing of pharmaceutical products and active pharmaceutical ingredients (APIs). Alembic Pharmaceuticals serves a global clientele with its diverse portfolio, which includes formulations, generics, and branded products. The company has a well-established presence in both domestic and international markets. Recently, Alembic Pharmaceuticals has been focusing on expanding its product portfolio and enhancing its manufacturing capabilities to cater to the growing demand in the healthcare sector.

Revenue

In the third quarter of the fiscal year 2026 (Q3FY26), Alembic Pharmaceuticals Ltd reported a total income of ₹1891.81 crores. This represents a slight decline of 1.3% compared to the previous quarter (Q2FY26), where the total income was ₹1917.06 crores. However, on a year-over-year basis, the company witnessed an increase of 11.1% from ₹1702.24 crores in Q3FY25. This growth in revenue over the year may reflect the company's efforts to expand its market reach and increase its product offerings.

Profitability

The company's profitability metrics for Q3FY26 show a profit before tax (PBT) of ₹163.33 crores, a decrease of 26.5% from ₹222.30 crores in Q2FY26. Year-over-year, the PBT declined by 7.9% from ₹177.42 crores in Q3FY25. The profit after tax (PAT) for Q3FY26 was ₹131.95 crores, down by 28.2% from ₹183.71 crores in the previous quarter. Compared to the same quarter last year, the PAT decreased by 4.2% from ₹137.70 crores. The company's earnings per share (EPS) also reflected this trend, with a value of ₹6.76 in Q3FY26, marking a 28.1% decline from ₹9.40 in Q2FY26 and a 3.6% decrease from ₹7.01 in Q3FY25.

Operating Metrics

The total expenses for Alembic Pharmaceuticals Ltd in Q3FY26 stood at ₹1686.25 crores, which is a marginal reduction of 0.5% from ₹1694.76 crores in the previous quarter. On an annual basis, total expenses increased by 10.6% from ₹1524.82 crores in Q3FY25. The tax expense for Q3FY26 was ₹29.54 crores, reflecting a decrease of 26.2% from ₹40.01 crores in Q2FY26 and a 26.3% decline from ₹40.08 crores in Q3FY25. This data highlights the changes in the company's operational cost structure over the periods examined.